Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;27(4):737-49, viii.
doi: 10.1016/j.hoc.2013.05.003. Epub 2013 Jun 18.

The management of early-stage and metastatic triple-negative breast cancer: a review

Carey K Anders  1 , Timothy M Zagar, Lisa A Carey
Affiliations
Review

The management of early-stage and metastatic triple-negative breast cancer: a review

Carey K Anders et al. Hematol Oncol Clin North Am. 2013 Aug.

Abstract

Triple-negative breast cancer (TNBC), defined as lacking expression of the estrogen receptor, progesterone receptor, and HER2, comprises approximately 15% of incident breast cancers and is over-represented among those with metastatic disease. There are several biologically distinct subtypes within TNBC. Although the incidence of BRCA mutations across all subsets of breast cancer is low, BRCA mutations are more common among those with TNBC and may have therapeutic implications. The general principles guiding the use of chemotherapy and radiation therapy do not differ dramatically between early-stage TNBC and non-TNBC.

Keywords: BRCA mutation; Breast cancer; Chemotherapy; Radiation; Targeted agents; Triple negative.

PubMed Disclaimer

Figures

Figure 1
Figure 1
General Algorithm Guiding Adjuvant Chemotherapy Decisions in the treatment of Early Stage Triple Negative Breast Cancer as adapted by www.NCCN.org, Version 1.2013, Invasive Breast Cancer
See this image and copyright information in PMC

References

    1. Swain S. Triple-Negative Breast Cancer: Metastatic Risk and Role of Platinum Agents. 2008 ASCO Clinical Science Symposium; June 3, 2008.2008.
    1. Nielsen T, Hsu F, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–5374. - PubMed
    1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. - PubMed
    1. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Research. 2008;68(9):3108–3114. - PubMed
    1. Dent R, Trudeau M, Pritchard K, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–4434. - PubMed